NBIX | Neurocrine Biosciences Inc Category: Consumer goods Industry: Drug Manufacturers - Major Quick infos Headquarters: San Diego, California, United States Trade prices Volume: Market Cap: 9.49B Prev closed: Open: High: Low: 52 week low: 52 week high: Dividends: No Dividends Next ER: May 3, 2023 Before Market Opens
About the Company
Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders.
Date EPS / Forecast Revenue / Forecast August 1, 2023 May 3, 2023 -0.51 / 0.63 410M / 410.82M February 6, 2023 1.24 / 1.12 412M / 408.87M Beat! November 1, 2022 1.08 / 0.8 387.9M / 376.55M Beat! August 4, 2022 -0.18 / 0.6194 378.2M / 342.33M Beat! view more Historical Data
Date Price Open High Low Vol Change ER May 2, 2023 103.45 103.28
849K -0.55% May 1, 2023 104.02 101.2
743K 2.95% Apr 28, 2023 101.04 101.28
940K -0.84% Apr 27, 2023 101.9 102.35
463K -0.8% Apr 26, 2023 102.72 101.46
471K 0.34% Apr 25, 2023 102.37 103.25
622K -1.15% Apr 24, 2023 103.56 104.12
489K -0.59% Apr 21, 2023 104.17 105
514K -0.37% Apr 20, 2023 104.56 104.67
513K -0.3% Apr 19, 2023 104.87 103.13
590K 1.11% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company Founded: 1992 Employees: 700 News Neurocrine Bio Tops Fourth-Quarter Views As Profit Skyrockets finance.yahoo.com Mar 31, 2023 8:56 am Analysts Are Revising Price Targets of These 10 Stocks Post Earnings finance.yahoo.com Mar 31, 2023 7:46 am Neurocrine Biosciences to Present at the Stifel 2023 CNS Days finance.yahoo.com Mar 21, 2023 4:01 pm Neurocrine Biosciences Announces Results from the Real-World RE-KINECT Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on Patient Health and Social Functioning finance.yahoo.com Mar 9, 2023 4:30 pm Neurocrine Biosciences to Participate at Investor Conferences in March finance.yahoo.com Mar 8, 2023 4:01 pm 2023 Rally Was a Bull Trap, Says Morgan Stanley. But These Stocks Still Have Upside finance.yahoo.com Mar 5, 2023 7:06 pm Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides finance.yahoo.com Feb 14, 2023 4:01 pm Dow Jones Rises Despite Microsoft Sell-Off; Beware 'Buying The Blip' finance.yahoo.com Feb 6, 2023 9:32 pm Neurocrine Reports 3,000% Profit Growth, But Shares Unexpectedly Tumble finance.yahoo.com Feb 6, 2023 4:05 pm Dow Jones Rises Ahead Of Earnings Season; Tesla Stock Continues To Rebound finance.yahoo.com Feb 6, 2023 10:05 am Dow Jones Rallies 275 Points After Jobless Claims; Tesla Stock Surges On Reiterated Buy Rating finance.yahoo.com Feb 6, 2023 9:57 am Dow Jones Futures Rise: Fed Rate Hike Looms, But This Is What Matters; Tesla Flirts With Buy Points investors.com Feb 6, 2023 8:19 am Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference finance.yahoo.com Feb 7, 2023 4:01 pm Dow Jones Rises Ahead Of Economic Data; Tesla Stock Hits New Low Amid Historic Plunge finance.yahoo.com Feb 6, 2023 9:54 am Dow Jones Rises After Housing Data; Tesla Plunges On Reduced Production Schedule In China finance.yahoo.com Feb 6, 2023 9:32 am Dow Jones Rises After Jobless Claims; Tesla Stock Surges On Reiterated Buy Rating finance.yahoo.com Feb 6, 2023 9:31 am Dow Jones Futures Rally On December Jobs Report; Tesla Stock Dives On China Price Cuts finance.yahoo.com Feb 6, 2023 9:24 am Dow Jones Futures Fall On Inflation Data; Tesla Stock Races Higher On Elon Musk Comments finance.yahoo.com Feb 6, 2023 9:22 am Neurocrine Biosciences, Voyager Therapeutics Collaborate For Neurological-Focused Gene Therapies finance.yahoo.com Feb 6, 2023 9:15 am Dow Jones Futures Rise Ahead Of Housing Data; Tesla Plunges On Reduced Production Schedule In China finance.yahoo.com Feb 6, 2023 9:00 am
This company doesn't provide a dividend.
Talk about Neurocrine Biosciences Inc below in comments section below.
Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
If you are looking for News & events, Press Release, they are available on their Investors Relationssite.
Consensus BUY 63 HOLD 31 SELL 6
If you want to help pay for server cost or for improving this tool. You can send it via
Paypal. More features coming soon :) Buy on Amazon
In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.